Indiana University School of Medicine researchers are taking a closer look at a disease whose incidence is rising as obesity in children increases.
Non-Alcoholic Steatohepatitis, more popularly known as Fatty Liver Disease, occurs in approximately 15% of obese children. Fatty Liver Disease, in which fat accumulates in the liver, while not life threatening in children, can lead to cirrhosis (scarring) of the liver, sometimes requiring transplantation by adulthood.
"Until now the only treatment for Fatty Liver Disease has been to offer diet and exercise counseling, but this is often not effective. As part of a national multi-center research network, we are now looking at Vitamin E and at Metformin, a drug used to treat Type II diabetes, as possible therapies" said Jean Molleston, M.D., clinical professor of pediatrics at IU School of Medicine and director of pediatric gastroenterology at Riley Hospital for Children. Dr. Molleston is the pediatric principal investigator for the IU School of Medicine site of TONIC, an eight-center Phase III study funded by the National Institute of Diabetes and Digestive and Kidney Disease, which is investigating treatment options for Fatty Liver Disease in 8 to 17 year olds and is the largest study of its type to date.